Efficacy and safety of necitumumab continuation therapy in the Phase III SQUIRE study of patients with stage IV squamous non-small-cell lung cancer.
Authors
Ciuleanu, TSocinski, M
Obasaju, C
Luft, A
Szczesna, A
Szafrański, W
Ramlau, R
Bálint, B
Molinier, O
Depenbrock, H
Nanda, S
Paz-Ares, L
Thatcher, Nick
Affiliation
Medical Oncology, Institute of Oncology Ion Chiricuta and UMF Iuliu Hatieganu, Cluj Napoca, RomaniaIssue Date
2017-10-13
Metadata
Show full item recordAbstract
In a retrospective analysis of the SQUamous NSCLC treatment with the Inhibitor of EGF REceptor (SQUIRE) study, we investigated the efficacy and safety of single-agent necitumumab continuation therapy in patients with stage IV squamous non-small-cell lung cancer and in a subpopulation of patients with epidermal growth factor receptor (EGFR)-expressing tumors.Citation
Efficacy and safety of necitumumab continuation therapy in the Phase III SQUIRE study of patients with stage IV squamous non-small-cell lung cancer 2017, Clin Lung CancerJournal
Clinical Lung CancerDOI
10.1016/j.cllc.2017.10.004PubMed ID
29158123Type
ArticleLanguage
enISSN
1938-0690ae974a485f413a2113503eed53cd6c53
10.1016/j.cllc.2017.10.004
Scopus Count
Collections
Related articles
- Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.
- Authors: Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch FR
- Issue date: 2016 Aug
- Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
- Authors: Reck M, Thomas M, Kropf-Sanchen C, Mezger J, Socinski MA, Depenbrock H, Soldatenkova V, Brown J, Krause T, Thatcher N
- Issue date: 2016
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
- Authors: Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA, SQUIRE Investigators.
- Issue date: 2015 Jul
- Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
- Authors: Park K, Cho EK, Bello M, Ahn MJ, Thongprasert S, Song EK, Soldatenkova V, Depenbrock H, Puri T, Orlando M
- Issue date: 2017 Oct
- An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
- Authors: Spigel DR, Luft A, Depenbrock H, Ramlau R, Khalil M, Kim JH, Mayo C, Chao GY, Obasaju C, Natale R
- Issue date: 2017 Sep